
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Incidence and clinical significance of recompensation after HCV-cure</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Incidence and clinical significance of recompensation after HCV-cure</strong></summary>
            <div>
                <ul><li>Study on recompensation after HCV-cure in patients with advanced chronic liver disease (ACLD).</li><li>Investigates incidence, impact, and predictors of recompensation after HCV-cure.</li><li>Retrospective study across 10 European centers.</li></ul>
                
        <details>
            <summary><strong>Methods</strong></summary>
            <div>
                <ul><li>Retrospective, observational cohort study.</li><li>Involved 2570 patients from 10 European centers.</li><li>Follow-up from 2014-2023.</li></ul>
                
        <details>
            <summary><strong>Patient Cohorts</strong></summary>
            <div>
                <ul><li>Decompensated Cirrhosis Cohort: 361 patients with decompensated cirrhosis achieving SVR after DAA treatment.</li><li>cACLD Cohort: 2209 patients with compensated ACLD (LSM ≥10kPa) undergoing DAA treatment.</li></ul>
                
        <details>
            <summary><strong>Inclusion Criteria (Decompensated Cirrhosis)</strong></summary>
            <div>
                <ul><li>History of ascites, variceal bleeding, or overt HE with underlying cirrhosis (LSM ≥15kPa, histology, or imaging).</li><li>DAA-treatment followed by SVR.</li><li>Sufficient pre- and post-treatment data.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Exclusion Criteria</strong></summary>
            <div>
                <ul><li>History of OLT, TIPS, or HCC before treatment.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Data Collection</strong></summary>
            <div>
                <ul><li>Liver disease severity (clinical, lab parameters) before treatment and at SVR assessment.</li><li>Clinical data: ascites severity, LVP history, HE severity, variceal status, PVT.</li><li>Alcohol consumption assessed semi-quantitatively.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Clinical Follow-up</strong></summary>
            <div>
                <ul><li>Occurrence of LVP, variceal bleeding, HE admissions, TIPS, PVT, HCC, death.</li><li>Followed until OLT, death, or last follow-up.</li><li>Ultrasound surveillance for HCC and PVT every 6 months.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Definitions</strong></summary>
            <div>
                <ul><li>Recompensation: Etiological cure (SVR) + resolution of ascites (off diuretics), encephalopathy (off lactulose/rifaximin) + absence of variceal hemorrhage (≥12 months) + stable improvement of liver function tests (albumin, INR, bilirubin).</li><li>Further decompensation: Baveno VII criteria, excluding jaundice.</li><li>Significant diuretic dose: spironolactone ≥100mg, eplerenone ≥100mg, furosemide ≥40mg, or torasemide ≥10mg.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Statistical Analysis</strong></summary>
            <div>
                <ul><li>R 4.4.1 used for analysis.</li><li>Continuous variables: median [IQR]. Categorical variables: proportion (%).</li><li>Mann-Whitney-U or Chi-squared tests for group comparisons.</li><li>Cox regression for time-to-event analyses, adjusting for center clustering.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Results</strong></summary>
            <div>
                <ul><li>Median follow-up: 8.4 years [IQR: 6.1-8.8].</li><li>137 (40.0%) died, 107 (29.6%) LRD, 26 (7.2%) OLT, 16 (4.4%) TIPS.</li><li>132 patients (36.6%) met recompensation definition.</li></ul>
                
        <details>
            <summary><strong>Recompensation Details</strong></summary>
            <div>
                <ul><li>28 (7.8%) recompensated at DAA initiation.</li><li>104 (28.8%) achieved recompensation after median 1.9 [0.7-3.6] years.</li><li>Recompensation incidence constant over time.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>HCC and PVT Incidence</strong></summary>
            <div>
                <ul><li>86 (23.8%) developed HCC.</li><li>70 (21.6% of 324) developed PVT, 22 (31.4%) after HCC.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Outcomes After Recompensation (n=132)</strong></summary>
            <div>
                <ul><li>25 (18.9%) developed another decompensating event.</li><li>24 (18.2%) developed HCC.</li><li>15 (12.1% of 124) developed PVT.</li><li>3 (2.3%) underwent OLT.</li><li>30 (22.7%) died.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Incidence Rates (IR) per 100 PY</strong></summary>
            <div>
                <ul><li>Death: cACLD 1.5, decompensated 7.2, after recompensation 4.2, before recompensation 8.8.</li><li>LRD: cACLD 0.6, after recompensation 2.6, before recompensation 7.2.</li><li>HCC: after recompensation 3.9, before recompensation 5.5.</li><li>PVT: after recompensation 2.7, before recompensation 5.4.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Association of Recompensation with Mortality</strong></summary>
            <div>
                <ul><li>Recompensation associated with lower LRD risk (aHR: 0.392 [95%CI: 0.230-0.668]) vs. no recompensation.</li><li>cACLD had lower risk (aHR vs. decompensated: 0.111 [95%CI: 0.073-0.171]).</li><li>Significant alcohol, diabetes, PVT also associated with LRD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Association of Recompensation with HCC and PVT</strong></summary>
            <div>
                <ul><li>HCC risk after recompensation not significantly different from decompensated (aHR: 0.738 [95%CI: 0.453-1.204]).</li><li>cACLD had significantly lower HCC risk.</li><li>Lower risk of PVT after recompensation (aHR: 0.421 [95%CI: 0.224-0.759]), but not comparable to cACLD.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Predictors of Recompensation (n=333)</strong></summary>
            <div>
                <ul><li>Diabetes (aHR: 0.595 [95%CI: 0.361-0.982]) and albumin levels (aHR per g/L: 1.079 [95%CI: 1.035-1.112]) independently associated with recompensation.</li><li>De-novo HCC seems to preclude recompensation.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Discussion</strong></summary>
            <div>
                <ul><li>37% of decompensated patients achieved recompensation.</li><li>Recompensation reduced liver-related mortality and PVT risk, but risks remained higher than cACLD.</li><li>Recompensation did not lower de-novo HCC incidence.</li></ul>
                
        <details>
            <summary><strong>Recompensation Rates Comparison</strong></summary>
            <div>
                <ul><li>Previous studies: 18% in ALD, 5.6%-60% in HBV, 25% in HCV.</li><li>Variations may reflect clinical practice or true differences across etiologies.</li><li>Advanced cohort with higher MELD may explain lower recompensation rate in other studies.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Predictors of Recompensation</strong></summary>
            <div>
                <ul><li>Low serum albumin and diabetes were negative predictors.</li><li>Albumin levels &gt;35 g/L linked to regression to CTP-stage A.</li><li>MELD score not predictive of clinical outcomes after etiological cure.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>HCC and Recompensation</strong></summary>
            <div>
                <ul><li>De-novo HCC after etiological cure impedes recompensation and is a strong predictor of mortality.</li><li>Recompensation not accompanied by statistically significantly lower HCC risk.</li><li>HCC surveillance warranted in recompensated patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>PVT and Recompensation</strong></summary>
            <div>
                <ul><li>Recompensation accompanied by lower PVT risk.</li><li>PVT associated with increased liver-related mortality.</li><li>Potential PVT underdiagnosis.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Limitations</strong></summary>
            <div>
                <ul><li>Retrospective design.</li><li>Heterogeneity in completeness of data.</li><li>Longitudinal assessment of alcohol consumption hampered.</li><li>Recompensation definition based on expert consensus.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Conclusion</strong></summary>
            <div>
                <ul><li>Validated prognostic value of Baveno VII criteria for recompensation in decompensated cirrhosis after HCV-cure.</li><li>Recompensated patients had lower LRD risk, but higher than cACLD.</li><li>PVT risk intermediate between cACLD and decompensated.</li><li>HCC risk not lowered by recompensation.</li><li>Low albumin and diabetes impeded recompensation.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Tables Summary</strong></summary>
            <div>
                <ul><li>Summaries of key tables from the study.</li></ul>
                
        <details>
            <summary><strong>Table 1: Patient Characteristics</strong></summary>
            <div>
                <ul><li>Compares characteristics of decompensated cirrhosis (n=361) and cACLD (n=2209) patients before and after HCV-cure.</li><li>Includes demographics, BMI, diabetes, alcohol consumption, HCV genotype, varices, ascites, HE, PVT, Child-Turcotte-Pugh stage, MELD, albumin, bilirubin, platelet count, and LSM.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Table 2: Incidence Rates of Clinical Endpoints</strong></summary>
            <div>
                <ul><li>Presents incidence rates (IR) per 100 patient-years (PY) for cACLD and decompensated cirrhosis (divided by recompensation status).</li><li>Outcomes: Death, liver-related death, HCC, and PVT.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Table 3: Multivariable Cox Regression for Liver-Related Mortality</strong></summary>
            <div>
                <ul><li>Shows factors associated with liver-related mortality in the overall cohort (n=2570).</li><li>Includes time-independent (age, sex, alcohol, diabetes) and time-dependent (ACLD stage, HCC, PVT, MELD, albumin) covariables.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Table 4: Predictors of Recompensation</strong></summary>
            <div>
                <ul><li>Presents univariable and multivariable Cox regression models for factors associated with recompensation in decompensated cirrhosis (excluding those recompensated before DAA).</li><li>Includes time-independent and time-dependent covariables.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
